EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection

Curtis J Donskey, Erik R Dubberke, Nicola P Klein, Elizabeth G Liles, Katarzyna Szymkowiak, Mark H Wilcox, Jody Lawrence, Salim Bouguermouh, Haiying Zhang, Kenneth Koury, Ruth Bailey, Helen M Smith und 9 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae410 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Curtis J Donskey und 20 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Clostridium Infections, Clostridioides difficile, Bacterial Vaccines, Bacterial Toxins. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clostridioides difficile infection (CDI) causes substantial mortality and healthcare burden. We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention.

Methods

This phase 3 observer-blinded study randomized (1:1) ≥50-year-olds at increased CDI risk (N = 17 535) to receive 3 PF-06425090 or placebo doses (0, 1, and 6 months). Primary end points were first CDI episode (≥3 unformed stools within 24 hours; central laboratory-confirmed toxin A/B positive) ≥14 days post-dose 3 (PD3; first primary) and post-dose 2 (PD2; second primary). CDI duration, need for CDI-related medical attention (secondary end points), and antibiotic use (post hoc analysis) PD3 were evaluated. Tolerability and safety were assessed.

Results

The primary end point was not met (17 PF-06425090 and 25 placebo recipients had first CDI episode ≥14 days PD3 [vaccine efficacy (VE) = 31.0% (96.4% confidence interval [CI], −38.7% to 66.6%)]; 24 PF-06425090 and 34 placebo recipients had first CDI episode ≥14 days PD2 [VE = 28.6% (96.4% CI, −28.4% to 61.0%)]. Median CDI duration was lower with PF-06425090 (1 day) versus placebo (4 days; 2-sided nominal P = .02). Of participants with first CDI episode, 0 PF-06425090 and 11 placebo recipients sought CDI-related medical attention (post hoc analysis estimated VE = 100%; 95% CI, 59.6% to 100.0%) and 0 PF-06425090 and 10 placebo recipients required antibiotic treatment (VE = 100%; 95% CI, 54.8% to 100.0%). Local reactions were more frequent in PF-06425090 recipients, and systemic events were generally similar between groups; most were mild to moderate. Adverse event rates were similar between groups.

Conclusions

Three PF-06425090 doses were safe and well tolerated. Although the primary end point was not met, PF-06425090 reduced symptom duration, CDI that required medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden. Clinical Trials Registration NCT03090191.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridium InfectionsClostridioides difficileBacterial VaccinesBacterial ToxinsHumansMaleFemaleMiddle AgedAgedAged, 80 and overEnterotoxinsBacterial Proteins

Stichwörter der Autor:innen

Clostridioides difficileClostridioides difficile infectionadultsinfectious diseasevaccine

Substanzen

Bacterial VaccinesBacterial ToxinsEnterotoxinsBacterial ProteinstoxB protein, Clostridium difficiletcdA protein, Clostridium difficile

Autor:innen und Institutionen

  • Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
  • Division of Infectious Diseases, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Kaiser Permanente Vaccine Study Center, Oakland, California, USA.
  • Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
  • Clinical Research, Synexus Polska Sp. z.o.o., Wroclaw, Poland.
  • Leeds Teaching Hospitals NHS Trust and Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.

Förderung

  • Pfizer

Zitieren

APA

Donskey, C. J., Dubberke, E. R., Klein, N. P., Liles, E. G., Szymkowiak, K., Wilcox, M. H., Lawrence, J., Bouguermouh, S., Zhang, H., Koury, K., Bailey, R., Smith, H. M., Lockhart, S., Lamberth, E., Kalina, W. V., Pride, M. W., Webber, C., Anderson, A. S., Jansen, K. U., …, & Kitchin, N. (2024). CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae410

Vancouver

Donskey CJ, Dubberke ER, Klein NP, Liles EG, Szymkowiak K, Wilcox MH, et al. CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae410

BibTeX
@article{Donskey2024,
  author = {Donskey, Curtis J and Dubberke, Erik R and Klein, Nicola P and Liles, Elizabeth G and Szymkowiak, Katarzyna and Wilcox, Mark H and Lawrence, Jody and Bouguermouh, Salim and Zhang, Haiying and Koury, Kenneth and Bailey, Ruth and Smith, Helen M and Lockhart, Stephen and Lamberth, Erik and Kalina, Warren V and Pride, Michael W and Webber, Chris and Anderson, Annaliesa S and Jansen, Kathrin U and Gruber, William C and Kitchin, Nicholas},
  title = {CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae410}
}
Kostenlos starten →